MindMed gets FANTASTIC News from the FDA, Causing its Stock to Skyrocket (MNMD/MMED) | Project Lucy
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
MindMed (Nasdaq: MNMD, NEO: MMED) today announced that their Flagship Program, Project Lucy, has been given the green light from the FDA. MindMed is set to start a phase 2b Clinical Trial treating Generalized Anxiety Disorder with MM-102.
In response, MindMed’s stock has SKYROCKETED! It is up 39% at the time of writing and it could go higher. The psychedelic stock has been battered over the last 8 months, so it is good to see positive news affecting the price.
MindMed is a company attempting to treat mental health conditions such as Anxiety and Depression with Psychedelic Therapies.
Can psychedelics relieve anxiety and treat mental health? MindMed wants to know!
#MNMDstock# MindMed #Psychedelics